Meeting
2024 ASCO Breakthrough
Dietary pattern and the corresponding gut microbiome in response to immunotherapy in Thai patients with advanced non-small cell lung cancer (NSCLC).
Authors
Piyada Sitthideatphaiboon
Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand
Piyada Sitthideatphaiboon , Nicha Somlaw , Nicha Zungsontiporn , Pongsakorn Ouwongprayoon , Narittee Sukswai , Krittiya Korphaisarn , Naravat Poungvarin , Chatchawit Aporntewan , Nattiya Hirankarn , Chanida Vinayanuwattikun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Immunotherapies
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 204)
DOI
10.1200/JCO.2024.42.23_suppl.204
Abstract #
204
Poster Bd #
J9
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I trial combining plinabulin and nivolumab for metastatic NSCLC: Trial in progress.
First Author: Nicolas Villanueva
Poster
2019 Genitourinary Cancers Symposium
Hyperprogressive disease in patients with metastatic genitourinary tumors treated with immune checkpoint inhibitors.
First Author: Cristina Suárez
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2024 ASCO Annual Meeting
Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.
First Author: Manish Sharma